

CITATION REPORT

List of articles citing

ACE2 and ADAM17 Interaction Regulates the Activity of Presympathetic Neurons

DOI: 10.1161/hypertensionaha.119.13133
Hypertension, 2019, 74, 1181-1191.

Source: <https://exaly.com/paper-pdf/72329880/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
64	ACE2 mouse models: a toolbox for cardiovascular and pulmonary research. <i>Nature Communications</i> , 2020 , 11, 5165	17.4	31
63	Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy gone viral? <i>Brain Communications</i> , 2020 , 2, fcaa149	4.5	4
62	Interactions of the Brain Renin-Angiotensin-System (RAS) and Inflammation in the Sensitization of Hypertension. <i>Frontiers in Neuroscience</i> , 2020 , 14, 650	5.1	13
61	Endocrine Significance of SARS-CoV-2's Reliance on ACE2. <i>Endocrinology</i> , 2020 , 161,	4.8	72
60	Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target. <i>Acta Pharmacologica Sinica</i> , 2021 , 42, 1390-1400	8	6
59	Comparative ACE2 variation and primate COVID-19 risk. <i>Communications Biology</i> , 2020 , 3, 641	6.7	83
58	ADAM17-Mediated Shedding of Inflammatory Cytokines in Hypertension. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1154	5.6	25
57	The Actin Bundling Protein Fascin-1 as an ACE2-Accessory Protein. <i>Cellular and Molecular Neurobiology</i> , 2020 , 1	4.6	3
56	Brain Testosterone-CYP1B1 (Cytochrome P450 1B1) Generated Metabolite 6β-Hydroxytestosterone Promotes Neurogenic Hypertension and Inflammation. <i>Hypertension</i> , 2020 , 76, 1006-1018	8.5	5
55	Sympathetic Activation in Hypertension: Importance of the Central Nervous System. <i>American Journal of Hypertension</i> , 2020 , 33, 914-926	2.3	11
54	Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19. <i>Journal of Cardiovascular Translational Research</i> , 2020 , 13, 894-899	3.3	34
53	Central CYP1B1 (Cytochrome P450 1B1)-Estradiol Metabolite 2-Methoxyestradiol Protects From Hypertension and Neuroinflammation in Female Mice. <i>Hypertension</i> , 2020 , 75, 1054-1062	8.5	11
52	Neuronal Networks in Hypertension: Recent Advances. <i>Hypertension</i> , 2020 , 76, 300-311	8.5	18
51	Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. <i>Brain, Behavior, and Immunity</i> , 2020 , 89, 579-586	16.6	125
50	COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 1109-1119	2.3	21
49	The Renin-Angiotensin System in the Central Nervous System and Its Role in Blood Pressure Regulation. <i>Current Hypertension Reports</i> , 2020 , 22, 7	4.7	31
48	Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. <i>Circulation Research</i> , 2020 , 126, 1456-1474 ¹⁰¹²	15.7	1012

47	Molecular chronicles of cytokine burst in patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 161, e217-e226	1.5	6
46	SARS-COV-2 (COVID-19) has neurotropic and neuroinvasive properties. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13708	2.9	6
45	Epigenetic modifications of the renin-angiotensin system in cardiometabolic diseases. <i>Clinical Science</i> , 2021 , 135, 127-142	6.5	4
44	Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. <i>Clinical Science</i> , 2021 , 135, 1-17	6.5	11
43	Contribution of ADAM17 and related ADAMs in cardiovascular diseases. <i>Cellular and Molecular Life Sciences</i> , 2021 , 78, 4161-4187	10.3	15
42	Angiotensin-Converting Enzyme Type 2 as a Molecular Mediator for Infection of Cells with SARS-CoV and SARS-CoV-2 Viruses. <i>Neuroscience and Behavioral Physiology</i> , 2021 , 51, 381-389	0.3	1
41	Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021 , 12, 655528	8.4	5
40	Hypertension, a Moving Target in COVID-19: Current Views and Perspectives. <i>Circulation Research</i> , 2021 , 128, 1062-1079	15.7	22
39	Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 136, 111193	7.5	14
38	Angiotensin-converting enzyme 2: a key enzyme in key organs. <i>Journal of Cardiovascular Medicine</i> , 2022 , 23, 1-11	1.9	1
37	Contemporary approach to understand and manage COVID-19-related arrhythmia. <i>Egyptian Heart Journal</i> , 2021 , 73, 76	1.3	2
36	Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	3
35	Sympathetic innervation of the mouse kidney and liver arising from prevertebral ganglia. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021 , 321, R328-R337	3.2	1
34	Renal denervation based on experimental rationale. <i>Hypertension Research</i> , 2021 , 44, 1385-1394	4.7	6
33	"The possible implication of endothelin in the pathology of COVID-19-induced pulmonary hypertension". <i>Pulmonary Pharmacology and Therapeutics</i> , 2021 , 71, 102082	3.5	5
32	Arginine vasopressin and pathophysiology of COVID-19: An innovative perspective. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 143, 112193	7.5	7
31	Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients. <i>Reviews in Medical Virology</i> , 2021 , 31, 1-12	11.7	22
30	Brain angiotensin converting enzyme-2 in central cardiovascular regulation. <i>Clinical Science</i> , 2020 , 134, 2535-2547	6.5	8

29	ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19. <i>Clinical Science</i> , 2020 , 134, 3047-3062	6.5	15
28	Comparative ACE2 variation and primate COVID-19 risk. 2020 ,		24
27	Syncope at SARS-CoV-2 onset due to impaired baroreflex response.		2
26	Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters.		12
25	Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. <i>GeroScience</i> , 2021 , 43, 2289-2304	8.9	5
24	Does damage to hypothalamic paraventricular nucleus underlie symptoms of ultradian rhythm disorder and an increased anxiety in coronavirus disease 2019?. <i>Croatian Medical Journal</i> , 2020 , 61, 377-386	1.6	3
23	OM-85 Broncho-Vaxom, a Bacterial Lysate, Reduces SARS-CoV-2 Binding Proteins on Human Bronchial Epithelial Cells. <i>Biomedicines</i> , 2021 , 9,	4.8	2
22	Activation of Kinin B1R Upregulates ADAM17 and Results in ACE2 Shedding in Neurons. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	4
21	COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme \square , Mutual Effects and Pharmacotherapy. <i>Frontiers in Endocrinology</i> , 2021 , 12, 772865	5.7	3
20	Effects of β Blockers on the Sympathetic and Cytokines Storms in Covid-19. <i>Frontiers in Immunology</i> , 2021 , 12, 749291	8.4	5
19	Understanding the Impact of the COVID-19 Pandemic, Lockdowns and Social Isolation on Sleep Quality. <i>Nature and Science of Sleep</i> , 2021 , 13, 2053-2064	3.6	5
18	Hypertension and its management in COVID-19 patients: The assorted view. <i>International Journal of Cardiology Cardiovascular Risk and Prevention</i> , 2021 , 11, 200121		6
17	Transforming Growth Factor- β Acts in Hypothalamic Paraventricular Nucleus to Upregulate ERK1/2 Signaling and Expression of Sympathoexcitatory Mediators in Heart Failure Rats.. <i>Neuroscience</i> , 2021 , 483, 13-13	3.9	0
16	ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease. <i>Advances in Pharmacology</i> , 2022 ,	5.7	0
15	The ACE2 Receptor for Coronavirus Entry Is Localized at Apical Cell-Cell Junctions of Epithelial Cells.. <i>Cells</i> , 2022 , 11,	7.9	2
14	Prevalence and patterns of symptoms of dysautonomia in patients with long-COVID syndrome: A cross-sectional study.. <i>Annals of Clinical and Translational Neurology</i> , 2022 ,	5.3	2
13	ADAM17, A Key Player of Cardiac Inflammation and Fibrosis in Heart Failure Development During Chronic Catecholamine Stress.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 732952	5.7	0
12	ACE2, Circumventricular Organs and the Hypothalamus, and COVID-19.. 2022 , 1		1

11	Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia. 2022 , 23,	1
10	The rationale for the treatment of long-Covid symptoms [A cardiologist's view. 9,	1
9	Involvement of shedding induced by ADAM17 on the nitric oxide pathway in hypertension. 9,	1
8	Co-Ultramicronized Palmitoylethanolamide/Luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndrome. 2022 ,	0
7	Immunomodulatory role of metalloproteinase ADAM17 in tumor development. 13,	2
6	The role of immune-inflammatory mechanisms in the pathogenesis of hypertension.	0
5	Investigating the possible mechanisms of autonomic dysfunction post-COVID-19. 2023 , 245, 103071	1
4	SARS-CoV-2 and Hypertension: Evidence Supporting Invasion into the Brain Via Baroreflex Circuitry and the Role of Imbalanced Renin-Angiotensin-Aldosterone-System. 2023 , 18, 263310552311519	0
3	Transgenic animal models for the functional analysis of ACE2. 2023 , 491-503	0
2	The role of immune-inflammatory mechanisms in the pathogenesis of hypertension. 2023 , 38, 21-27	0
1	P38 MAPK activated ADAM17 mediates ACE2 shedding and promotes cardiac remodeling and heart failure after myocardial infarction. 2023 , 21,	0